Which has better valuation and earnings, RLMD or AARD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is RLMD or AARD more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -47.52% -43.97% Aardvark Therapeutics N/A -71.54% -64.94%

Do analysts prefer CGC or AARD?

Aardvark Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 175.78%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.42

Does the media prefer CGC or AARD?

In the previous week, Canopy Growth had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 22 mentions for Canopy Growth and 21 mentions for Aardvark Therapeutics. Canopy Growth's average media sentiment score of 1.09 beat Aardvark Therapeutics' score of 0.03 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 11 Very Positive mention(s) 8 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, AVIR or AARD?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is AVIR or AARD more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Aardvark Therapeutics N/A -71.54% -64.94%

Does the media prefer SPRY or AARD?

In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 21 articles in the media. ARS Pharmaceuticals' average media sentiment score of 0.12 beat Aardvark Therapeutics' score of 0.03 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, AARD or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is AARD or TTRX more profitable?

Aardvark Therapeutics' return on equity of -71.54% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Turn Therapeutics N/A -230.84% -53.19%

Does the media favor AARD or TTRX?

In the previous week, Aardvark Therapeutics had 19 more articles in the media than Turn Therapeutics. MarketBeat recorded 21 mentions for Aardvark Therapeutics and 2 mentions for Turn Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.03 beat Turn Therapeutics' score of -0.17 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Aardvark Therapeutics (AARD) Competitors

$5.56 -0.19 (-3.30%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$5.58 +0.03 (+0.45%)

As of 09/23/2026 07:30 PM Eastern

Compare

AARD vs. RLMD, CGC, AVIR, SPRY, and TTRX

Should you buy Aardvark Therapeutics stock or one of its competitors? Aardvark Therapeutics's main competitors and comparable companies include Relmada Therapeutics (RLMD), Canopy Growth (CGC), Atea Pharmaceuticals (AVIR), ARS Pharmaceuticals (SPRY), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Relmada Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 217.46%. Aardvark Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 175.78%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

Relmada Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.74, suggesting that its stock price is 274% more volatile than the broader market.

45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Relmada Therapeutics' return on equity of -47.52% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

In the previous week, Aardvark Therapeutics had 21 more articles in the media than Relmada Therapeutics. MarketBeat recorded 21 mentions for Aardvark Therapeutics and 0 mentions for Relmada Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.03 beat Relmada Therapeutics' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Relmada Therapeutics	Neutral
Aardvark Therapeutics	Neutral

Summary

Relmada Therapeutics beats Aardvark Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

3.3% of Canopy Growth shares are held by institutional investors. 0.4% of Canopy Growth shares are held by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aardvark Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Canopy Growth has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.74, meaning that its share price is 274% more volatile than the broader market.

In the previous week, Canopy Growth had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 22 mentions for Canopy Growth and 21 mentions for Aardvark Therapeutics. Canopy Growth's average media sentiment score of 1.09 beat Aardvark Therapeutics' score of 0.03 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	11 Very Positive mention(s)	8 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aardvark Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 175.78%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

Aardvark Therapeutics has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$293.63M	1.43	-$190.29M	-$0.45	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Summary

Aardvark Therapeutics beats Canopy Growth on 9 of the 16 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Atea Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.74, meaning that its stock price is 274% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 21 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 21 mentions for Aardvark Therapeutics and 0 mentions for Atea Pharmaceuticals. Aardvark Therapeutics' average media sentiment score of 0.03 beat Atea Pharmaceuticals' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Aardvark Therapeutics	Neutral

Atea Pharmaceuticals' return on equity of -64.25% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Atea Pharmaceuticals presently has a consensus target price of $7.00, suggesting a potential upside of 32.58%. Aardvark Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 175.78%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Summary

Aardvark Therapeutics beats Atea Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Aardvark Therapeutics compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ARS Pharmaceuticals currently has a consensus price target of $26.40, suggesting a potential upside of 531.58%. Aardvark Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 175.78%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe ARS Pharmaceuticals is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

ARS Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.74, meaning that its share price is 274% more volatile than the broader market.

Aardvark Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	4.93	-$171.30M	-$2.18	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 21 articles in the media. ARS Pharmaceuticals' average media sentiment score of 0.12 beat Aardvark Therapeutics' score of 0.03 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aardvark Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Aardvark Therapeutics' return on equity of -71.54% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Summary

Aardvark Therapeutics beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Turn Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

In the previous week, Aardvark Therapeutics had 19 more articles in the media than Turn Therapeutics. MarketBeat recorded 21 mentions for Aardvark Therapeutics and 2 mentions for Turn Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.03 beat Turn Therapeutics' score of -0.17 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aardvark Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 175.78%. Turn Therapeutics has a consensus price target of $9.00, indicating a potential downside of 33.38%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aardvark Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Turn Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Aardvark Therapeutics' return on equity of -71.54% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Turn Therapeutics	N/A	-230.84%	-53.19%

Summary

Aardvark Therapeutics beats Turn Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AARD vs. The Competition

Export

Metric	Aardvark Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$125.83M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-1.73	792.28	274.02	25.69
Price / Sales	N/A	860.20	633.28	76.04
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.13	10.62	10.44	6.32
Net Income	-$57.59M	$2.81B	$3.49B	$359.73M
7 Day Performance	0.54%	-0.08%	-0.66%	0.17%
1 Month Performance	-19.19%	-1.31%	-3.16%	-3.27%
1 Year Performance	-54.31%	2.91%	15.15%	5.58%

Aardvark Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AARD Aardvark Therapeutics	3.4494 of 5 stars	$5.56 -3.3%	$15.33 +175.8%	-51.4%	$125.83M	N/A	N/A	28	Trending News
RLMD Relmada Therapeutics	1.8136 of 5 stars	$4.12 -1.9%	$12.00 +191.3%	+126.3%	$448.01M	N/A	N/A	17	Positive News
CGC Canopy Growth	1.0689 of 5 stars	$0.93 -0.5%	N/A	-28.6%	$421.94M	$251.01M	N/A	1,128	Trending News Options Volume
AVIR Atea Pharmaceuticals	1.7434 of 5 stars	$5.33 +1.3%	$7.00 +31.3%	+82.1%	$421.88M	N/A	N/A	55	High Trading Volume
SPRY ARS Pharmaceuticals	1.7375 of 5 stars	$4.11 -1.0%	$26.40 +542.3%	-57.9%	$412.71M	$84.28M	N/A	200	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aardvark Therapeutics (AARD) Competitors

AARD vs. RLMD, CGC, AVIR, SPRY, and TTRX

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Summary

How does Aardvark Therapeutics compare to Canopy Growth?

Summary

How does Aardvark Therapeutics compare to Atea Pharmaceuticals?

Summary

How does Aardvark Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Aardvark Therapeutics compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aardvark Therapeutics (AARD) Competitors

AARD vs. RLMD, CGC, AVIR, SPRY, and TTRX

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Which has better valuation and earnings, RLMD or AARD?

Do analysts rate RLMD or AARD?

Which has more volatility and risk, RLMD or AARD?

Do insiders and institutionals have more ownership in RLMD or AARD?

Is RLMD or AARD more profitable?

Does the media favor RLMD or AARD?

Summary

How does Aardvark Therapeutics compare to Canopy Growth?

Do institutionals and insiders hold more shares of CGC or AARD?

Is CGC or AARD more profitable?

Which has more volatility and risk, CGC or AARD?

Does the media prefer CGC or AARD?

Do analysts prefer CGC or AARD?

Which has higher earnings & valuation, CGC or AARD?

Summary

How does Aardvark Therapeutics compare to Atea Pharmaceuticals?

Do institutionals & insiders have more ownership in AVIR or AARD?

Which has more volatility & risk, AVIR or AARD?

Does the media favor AVIR or AARD?

Is AVIR or AARD more profitable?

Do analysts prefer AVIR or AARD?

Which has stronger earnings & valuation, AVIR or AARD?

Summary

How does Aardvark Therapeutics compare to ARS Pharmaceuticals?

Do insiders and institutionals have more ownership in SPRY or AARD?

Do analysts prefer SPRY or AARD?

Which has more volatility & risk, SPRY or AARD?

Which has better earnings and valuation, SPRY or AARD?

Does the media prefer SPRY or AARD?

Is SPRY or AARD more profitable?

Summary

How does Aardvark Therapeutics compare to Turn Therapeutics?

Does the media favor AARD or TTRX?

Do analysts recommend AARD or TTRX?

Which has preferable valuation & earnings, AARD or TTRX?

Is AARD or TTRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools